Completed PHASE3 INTERVENTIONAL 2-arm NCT01442727

Selenium in the Treatment of Arsenic Toxicity and Cancers (SETAC)

Selenite in the Detoxification of Arsenic and the Prevention of Arsenical Melanosis and Cancers Amongst Bangladeshi Arsenicosis Patients: A 48-week, Randomized, Double-blinded, Placebo-controlled Phase III Trial

Sponsor: American Cancer Society, Inc.

Conditions Arsenic Exposure Arsenic Poisoning Arsenic Toxicity Arsenical Cancers Arsenical Keratosis Arsenical Melanosis Arsenicosis

Interventions placebo sodium selenite

Updated 6 times since 2017 Last updated: Oct 6, 2011 Started: Dec 31, 2006 Primary completion: Apr 30, 2009 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Arsenic Exposure and Arsenic Poisoning and is currently completed. American Cancer Society, Inc. leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

American Cancer Society, Inc.
National Cancer Institute (NCI)
Texas Tech University

Data source: Texas Tech University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kalibari Town, Bangladesh